{"id":11125,"date":"2025-06-20T16:51:23","date_gmt":"2025-06-20T16:51:23","guid":{"rendered":"https:\/\/www.merck.ca\/en\/?page_id=11125"},"modified":"2025-06-20T16:51:25","modified_gmt":"2025-06-20T16:51:25","slug":"merck-digital-sciences-studio-opens-in-canada-to-accelerate-biopharmaceutical-innovation","status":"publish","type":"page","link":"https:\/\/www.merck.ca\/en\/newsroom\/merck-digital-sciences-studio-opens-in-canada-to-accelerate-biopharmaceutical-innovation\/","title":{"rendered":"Merck Digital Sciences Studio Opens in Canada to Accelerate Biopharmaceutical Innovation"},"content":{"rendered":"\n<h1 class=\"wp-block-heading\"><strong><strong>Merck Digital Sciences Studio Opens in Canada to Accelerate Biopharmaceutical Innovation<\/strong><\/strong><\/h1>\n\n\n\n<p class=\"has-text-align-center\"><strong><strong>New accelerator program to support startups with funding, mentorship and technology resources<\/strong><\/strong><\/p>\n\n\n\n<p class=\"has-text-align-right\"><a href=\"https:\/\/www.merck.ca\/en\/wp-content\/uploads\/sites\/20\/2025\/06\/Press-Release-Launch-of-MDSS-in-Canada.pdf\" rel=\"noreferrer noopener\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"16\" height=\"16\" viewBox=\"0 0 16 16\">     <path fill=\"#00857C\" d=\"M2.556 3.894v9.326h10.888V3.894H15v9.326c0 .863-.7 1.555-1.556 1.555H2.556A1.555 1.555 0 0 1 1 13.22V3.894h1.556zM8.924.775v8.59L10.9 7.391l1.1 1.1-3.85 3.85-3.85-3.85 1.1-1.1 1.974 1.974V.775h1.551z\"> <\/path><\/svg> Download<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-css-opacity is-style-wide\"\/>\n\n\n\n<p class=\"has-text-align-center\"><\/p>\n\n\n\n<p>KIRKLAND, QC., June 20, 2025 \u2013 Merck, known as MSD outside of the United States and Canada, is proud to announce the opening of the Merck Digital Sciences Studio (MDSS) in Montr\u00e9al, Canada, a collaborative startup accelerator dedicated to investing in, supporting and mentoring biopharmaceutical startups focused on developing cutting-edge digital technologies. The MDSS specifically targets innovations in preventive health, platforms for biologics research and development (R&amp;D) and 3D translational disease models.<\/p>\n\n\n\n<p>Designed for startups incorporated in Qu\u00e9bec or Canada and set to commence in July 2025, the six-month acceleration program will provide <a href=\"https:\/\/www.mds.studio\/companies\">seven selected startups<\/a> with access to mentoring from experts at Merck and Centech. Each selected startup will receive funding through either the Merck Global Health Innovation Fund and the CQDM or Merck Canada. Selected participants will also benefit from tailored guidance, specialized sessions with industry leaders and increased exposure to Merck\u2019s decision-makers, paving the way for long-term collaborations.<\/p>\n\n\n\n<p>The selected start-ups that will join the six-month acceleration program in Montr\u00e9al include<sup>1<\/sup>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Nanofacile<\/strong> \u2013 Accelerating RNA therapy development for biotech, CROs and pharma by offering a first-in-class, intuitive and easy-to-use \u201cNanomedicine in a Box\u201d technology platform kit.<\/li>\n\n\n\n<li><strong>Simmunome<\/strong> \u2013 Building AI validation infrastructure for robust, safe and equitable health care AI algorithms that help enhance the predictability of clinical drug development to prevent late-stage failures.<\/li>\n\n\n\n<li><strong>Misochip<\/strong> \u2013 Reducing cancer clinical trial failure rates due to poor efficacy using functional precision medicine for preclinical solutions that allow ex vivo testing on human-relevant tumor models to identify potent drivers of efficacy or resistance.<\/li>\n\n\n\n<li><strong>9Bio<\/strong> \u2013 Unlocking the full potential of targeted therapies by guiding antibodies to the right location and accelerating the discovery of conditionally active targeted therapeutics with an integrated methodology.<\/li>\n\n\n\n<li><strong>Rime Therapeutics<\/strong> <a>\u2013<\/a> Driving precision therapies powered by deep understanding of inflammation biology through a proprietary function-first target and hit discovery platform which unlocks protein-protein interactions (PPIs).<\/li>\n\n\n\n<li><strong>Stereo Bio<\/strong> \u2013 Addressing cellular heterogeneity in disease with purpose-built multi-specific pMHC-targeting therapeutics, starting with solid tumors.<\/li>\n\n\n\n<li><strong>PCare+<\/strong> \u2013 Transforming complex medical guidelines into actionable digital formats using AI by combining large language models (LLMs) with expert systems to extract screening recommendations, scoring systems, and decision logic from guidelines.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><sup>1<\/sup> <em>*Note: Access to certain benefits may vary among select start-ups.<\/em><\/p>\n\n\n\n<p>The Quebec government has allocated $900,000 to this initiative through the Quebec Life Sciences Strategy 2022-2025.<\/p>\n\n\n\n<p>\u201cNow more than ever, we need to place a strong focus on collaborative research\u2014it\u2019s how we can develop the future-proof technologies that will keep Qu\u00e9bec competitive at home and abroad. Congratulations to Merck, Centech and CQDM on this exciting partnership, which will give seven up-and-coming companies the chance to play a role in advancing new therapeutic solutions,\u201d says Christopher Skeete, Minister for the Economy, Minister Responsible for the Fight Against Racism and Minister Responsible for the Laval Region.<\/p>\n\n\n\n<p>\u201cWe are excited to expand our accelerator footprint globally as more digital health startups continue to drive forward new patient solutions,\u201d said David Rubin, Managing Director at Merck Global Health Innovation Fund. \u201cThe role of computational biology is evolving beyond tools like machine learning to newer language learning models and neural networks, and being on the forefront of that evolution across regions has the potential to positively impact drug development for the pharma industry.\u201d<\/p>\n\n\n\n<p>\u201cBy fostering a collaborative environment, the MDSS will empower startups to leverage the latest advancements in technology and science,\u201d said David D. Jones, Managing Director of Merck Canada. \u201cWe believe that innovation thrives in partnerships, and through this initiative, we aim to create a vibrant ecosystem that accelerates the development of transformative health solutions.\u201d<\/p>\n\n\n\n<p>\u201cThe launch of this studio underscores CQDM\u2019s commitment to building high-impact partnerships that accelerate innovation from early-stage discovery to digital transformation,\u201d said V\u00e9ronique Dugas, CEO of CQDM. \u201cWe are proud to collaborate with Merck \u2014 a valued partner for over 16 years \u2014 on an initiative that leverages Canada\u2019s, and particularly Qu\u00e9bec\u2019s, world-class strengths in artificial intelligence and biopharmaceutical research. This partnership reinforces CQDM\u2019s role in advancing life sciences and strengthening Canada\u2019s innovation ecosystem.\u201d<\/p>\n\n\n\n<p>&#8220;This partnership with Merck reinforces our commitment to supporting the next generation of deeptech entrepreneurs in Canada,\u201d said Marjorick Foisy, General Director of Centech. \u201cBy combining Centech\u2019s expertise in open innovation with Merck\u2019s global leadership in life sciences, the Merck Digital Sciences Studio will help foster breakthrough innovations and strengthen the Canadian digital health ecosystem.&#8221;<\/p>\n\n\n\n<p><strong><strong><strong><strong><strong><strong><strong>About Merck Digital Science Studio<\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/p>\n\n\n\n<p>The Merck Digital Sciences Studio (MDS Studio, or MDSS) is an accelerator program providing mentorship, coaching, training, support, community, and investment to enable the next generation of innovative technologies for drug discovery and development. We invest in disruptive and innovative startups in digital biopharma via a SAFE (Simple Agreement for Future Equity). The MDS Studio\u2019s unique design and network empowers startups to engage with industry leading partners, who take an active role in development. Learn more by visiting <a href=\"https:\/\/www.mds.studio\">www.mds.studio<\/a>.<\/p>\n\n\n\n<p><strong><strong><strong><strong>About Merck<\/strong><\/strong><\/strong><\/strong><\/p>\n\n\n\n<p>At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world \u2013 and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities.&nbsp;For more information about our operations in Canada, visit&nbsp;<a href=\"http:\/\/www.merck.ca\/\">www.merck.ca<\/a>&nbsp;and connect with us on&nbsp;<a href=\"https:\/\/www.linkedin.com\/company\/merck-canada\/\">LinkedIn<\/a> @MerckCanada.<\/p>\n\n\n\n<p><strong>About the CQDM<\/strong><br><em>Biopharma Innovation Facilitator<\/em><\/p>\n\n\n\n<p>CQDM is a not-for-profit biopharmaceutical research consortium whose mission is to support and facilitate collaborative multi-stakeholder research and development aimed at accelerating the translation or transformation of innovative technologies into solutions to unmet medical needs, while generating significant benefits for the Qu\u00e9bec and Canadian economy. For more information, consult our website&nbsp;<a href=\"https:\/\/cqdm.org\/en\/\">https:\/\/cqdm.org\/en\/<\/a>&nbsp;and join us on Twitter\/X&nbsp;<a href=\"https:\/\/can01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fx.com%2FCQDM_Canada&amp;data=05%7C02%7Canouk.boislard.hsj%40ssss.gouv.qc.ca%7C2cd697618d8343ce0eac08dd73a893a1%7C06e1fe285f8b4075bf6cae24be1a7992%7C0%7C0%7C638793890091965205%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=ajwRpAmaWF1vNYSubgC984pokD7uf0HxhFr%2Ffko9dW4%3D&amp;reserved=0\" target=\"_blank\" rel=\"noreferrer noopener\">@CQDM_Canada<\/a>&nbsp;and&nbsp;<a href=\"https:\/\/can01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fcqdm%2F&amp;data=05%7C02%7Canouk.boislard.hsj%40ssss.gouv.qc.ca%7C2cd697618d8343ce0eac08dd73a893a1%7C06e1fe285f8b4075bf6cae24be1a7992%7C0%7C0%7C638793890091978817%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=LjK2N0go3Op%2Fm2jcXqjleMuBcFopkr1ogdh0wAZYGr4%3D&amp;reserved=0\" target=\"_blank\" rel=\"noreferrer noopener\">LinkedIn.<\/a><\/p>\n\n\n\n<p><strong><strong><strong><strong><strong>Forward-Looking Statement of Merck &amp; Co., Inc., Rahway, N.J., USA<\/strong><\/strong><\/strong><\/strong><\/strong><\/p>\n\n\n\n<p>This news release of Merck &amp; Co., Inc., Rahway, N.J., USA (the \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company\u2019s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.<\/p>\n\n\n\n<p>&nbsp;Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company\u2019s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company\u2019s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and\/or regulatory actions.<\/p>\n\n\n\n<p>The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company\u2019s Annual Report on Form 10-K for the year ended December 31, 2024 and the company\u2019s other filings with the Securities and Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/www.sec.gov\">www.sec.gov<\/a>).<\/p>\n\n\n\n<p class=\"has-text-align-center\"><strong>###<\/strong><\/p>\n\n\n\n<p style=\"font-size:12px\">\u00a9 2025 Merck &amp; Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck Digital Sciences Studio Opens in Canada to Accelerate Biopharmaceutical Innovation New accelerator program to support startups with funding, mentorship and technology resources Download KIRKLAND, QC., June 20, 2025 \u2013 Merck, known as MSD outside of the United States and Canada, is proud to announce the opening of the Merck Digital Sciences Studio (MDSS) in [&hellip;]<\/p>\n","protected":false},"author":1049,"featured_media":0,"parent":2059,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"editor_notices":[],"footnotes":""},"class_list":["post-11125","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.9.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Merck Digital Sciences Studio Opens in Canada to Accelerate Biopharmaceutical Innovation - Merck Canada<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merck.ca\/en\/newsroom\/merck-digital-sciences-studio-opens-in-canada-to-accelerate-biopharmaceutical-innovation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Digital Sciences Studio Opens in Canada to Accelerate Biopharmaceutical Innovation - Merck Canada\" \/>\n<meta property=\"og:description\" content=\"Merck Digital Sciences Studio Opens in Canada to Accelerate Biopharmaceutical Innovation New accelerator program to support startups with funding, mentorship and technology resources Download KIRKLAND, QC., June 20, 2025 \u2013 Merck, known as MSD outside of the United States and Canada, is proud to announce the opening of the Merck Digital Sciences Studio (MDSS) in [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merck.ca\/en\/newsroom\/merck-digital-sciences-studio-opens-in-canada-to-accelerate-biopharmaceutical-innovation\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck Canada\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-20T16:51:25+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.merck.ca\/en\/newsroom\/merck-digital-sciences-studio-opens-in-canada-to-accelerate-biopharmaceutical-innovation\/\",\"url\":\"https:\/\/www.merck.ca\/en\/newsroom\/merck-digital-sciences-studio-opens-in-canada-to-accelerate-biopharmaceutical-innovation\/\",\"name\":\"Merck Digital Sciences Studio Opens in Canada to Accelerate Biopharmaceutical Innovation - Merck Canada\",\"isPartOf\":{\"@id\":\"https:\/\/www.merck.ca\/en\/#website\"},\"datePublished\":\"2025-06-20T16:51:23+00:00\",\"dateModified\":\"2025-06-20T16:51:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.merck.ca\/en\/newsroom\/merck-digital-sciences-studio-opens-in-canada-to-accelerate-biopharmaceutical-innovation\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.merck.ca\/en\/newsroom\/merck-digital-sciences-studio-opens-in-canada-to-accelerate-biopharmaceutical-innovation\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.merck.ca\/en\/newsroom\/merck-digital-sciences-studio-opens-in-canada-to-accelerate-biopharmaceutical-innovation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News Releases\",\"item\":\"https:\/\/www.merck.ca\/en\/newsroom\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Digital Sciences Studio Opens in Canada to Accelerate Biopharmaceutical Innovation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.merck.ca\/en\/#website\",\"url\":\"https:\/\/www.merck.ca\/en\/\",\"name\":\"Merck Canada\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.merck.ca\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Digital Sciences Studio Opens in Canada to Accelerate Biopharmaceutical Innovation - Merck Canada","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merck.ca\/en\/newsroom\/merck-digital-sciences-studio-opens-in-canada-to-accelerate-biopharmaceutical-innovation\/","og_locale":"en_US","og_type":"article","og_title":"Merck Digital Sciences Studio Opens in Canada to Accelerate Biopharmaceutical Innovation - Merck Canada","og_description":"Merck Digital Sciences Studio Opens in Canada to Accelerate Biopharmaceutical Innovation New accelerator program to support startups with funding, mentorship and technology resources Download KIRKLAND, QC., June 20, 2025 \u2013 Merck, known as MSD outside of the United States and Canada, is proud to announce the opening of the Merck Digital Sciences Studio (MDSS) in [&hellip;]","og_url":"https:\/\/www.merck.ca\/en\/newsroom\/merck-digital-sciences-studio-opens-in-canada-to-accelerate-biopharmaceutical-innovation\/","og_site_name":"Merck Canada","article_modified_time":"2025-06-20T16:51:25+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merck.ca\/en\/newsroom\/merck-digital-sciences-studio-opens-in-canada-to-accelerate-biopharmaceutical-innovation\/","url":"https:\/\/www.merck.ca\/en\/newsroom\/merck-digital-sciences-studio-opens-in-canada-to-accelerate-biopharmaceutical-innovation\/","name":"Merck Digital Sciences Studio Opens in Canada to Accelerate Biopharmaceutical Innovation - Merck Canada","isPartOf":{"@id":"https:\/\/www.merck.ca\/en\/#website"},"datePublished":"2025-06-20T16:51:23+00:00","dateModified":"2025-06-20T16:51:25+00:00","breadcrumb":{"@id":"https:\/\/www.merck.ca\/en\/newsroom\/merck-digital-sciences-studio-opens-in-canada-to-accelerate-biopharmaceutical-innovation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merck.ca\/en\/newsroom\/merck-digital-sciences-studio-opens-in-canada-to-accelerate-biopharmaceutical-innovation\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.merck.ca\/en\/newsroom\/merck-digital-sciences-studio-opens-in-canada-to-accelerate-biopharmaceutical-innovation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News Releases","item":"https:\/\/www.merck.ca\/en\/newsroom\/"},{"@type":"ListItem","position":2,"name":"Merck Digital Sciences Studio Opens in Canada to Accelerate Biopharmaceutical Innovation"}]},{"@type":"WebSite","@id":"https:\/\/www.merck.ca\/en\/#website","url":"https:\/\/www.merck.ca\/en\/","name":"Merck Canada","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merck.ca\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.merck.ca\/en\/wp-json\/wp\/v2\/pages\/11125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merck.ca\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.merck.ca\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.merck.ca\/en\/wp-json\/wp\/v2\/users\/1049"}],"replies":[{"embeddable":true,"href":"https:\/\/www.merck.ca\/en\/wp-json\/wp\/v2\/comments?post=11125"}],"version-history":[{"count":7,"href":"https:\/\/www.merck.ca\/en\/wp-json\/wp\/v2\/pages\/11125\/revisions"}],"predecessor-version":[{"id":11134,"href":"https:\/\/www.merck.ca\/en\/wp-json\/wp\/v2\/pages\/11125\/revisions\/11134"}],"up":[{"embeddable":true,"href":"https:\/\/www.merck.ca\/en\/wp-json\/wp\/v2\/pages\/2059"}],"wp:attachment":[{"href":"https:\/\/www.merck.ca\/en\/wp-json\/wp\/v2\/media?parent=11125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}